Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis

OBJECTIVES: The cytokine oncostatin M (OSM) is implicated in the pathology of SSc. Inhibiting OSM signalling using GSK2330811 (an anti-OSM monoclonal antibody) in patients with SSc has the potential to slow or stop the disease process. METHODS: This multicentre, randomized, double-blind, placebo-con...

Descripción completa

Detalles Bibliográficos
Autores principales: Denton, Christopher P, del Galdo, Francesco, Khanna, Dinesh, Vonk, Madelon C, Chung, Lorinda, Johnson, Sindhu R, Varga, John, Furst, Daniel E, Temple, Jane, Zecchin, Chiara, Csomor, Eszter, Lee, Amy, Wisniacki, Nicolas, Flint, Shaun M, Reid, Juliet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788816/
https://www.ncbi.nlm.nih.gov/pubmed/35583273
http://dx.doi.org/10.1093/rheumatology/keac300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788816/
https://www.ncbi.nlm.nih.gov/pubmed/35583273
http://dx.doi.org/10.1093/rheumatology/keac300

Ejemplares similares